These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29705996)

  • 1. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
    Dickel H; Bruckner T; Altmeyer P
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis.
    Dickel H; Bruckner T; Höxtermann S; Dickel B; Trinder E; Altmeyer P
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):893-905. PubMed ID: 30680823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral fumaric acid esters for psoriasis.
    Atwan A; Ingram JR; Abbott R; Kelson MJ; Pickles T; Bauer A; Piguet V
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010497. PubMed ID: 26258748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
    Tzaneva S; Geroldinger A; Trattner H; Tanew A
    Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
    Mason KJ; Williams S; Yiu ZZN; McElhone K; Ashcroft DM; Kleyn CE; Jabbar-Lopez ZK; Owen CM; Reynolds NJ; Smith CH; Wilson N; Warren RB; Griffiths CEM
    Br J Dermatol; 2019 Aug; 181(2):256-264. PubMed ID: 30628069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
    Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M
    Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
    Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
    Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fumaric acid esters for psoriasis: a systematic review.
    Smith D
    Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
    Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate-to-severe plaque psoriasis (FAST).
    Weisenseel P; Reich K; Griemberg W; Merten K; Gröschel C; Gomez NN; Taipale K; Bräu B; Zschocke I
    J Dtsch Dermatol Ges; 2017 Feb; 15(2):180-186. PubMed ID: 28214304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
    Wilsmann-Theis D; Frambach Y; Philipp S; Weyergraf AJ; Jacobi A; Mössner R; Gerdes S
    Dermatology; 2015; 230(2):119-27. PubMed ID: 25661583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.
    Mrowietz U; Christophers E; Altmeyer P
    Br J Dermatol; 1998 Mar; 138(3):456-60. PubMed ID: 9580799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies.
    Balak DM; Fallah Arani S; Hajdarbegovic E; Hagemans CA; Bramer WM; Thio HB; Neumann HA
    Br J Dermatol; 2016 Aug; 175(2):250-62. PubMed ID: 26919824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.
    Hoefnagel JJ; Thio HB; Willemze R; Bouwes Bavinck JN
    Br J Dermatol; 2003 Aug; 149(2):363-9. PubMed ID: 12932244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fumaric acid esters in the management of severe psoriasis.
    Brewer L; Rogers S
    Clin Exp Dermatol; 2007 May; 32(3):246-9. PubMed ID: 17362235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study).
    Reich K; Hartl C; Gambichler T; Zschocke I
    J Dtsch Dermatol Ges; 2016 Jan; 14(1):50-8. PubMed ID: 26713639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
    Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
    Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial.
    Balak DM; Fallah-Arani S; Venema CM; Neumann HA; Thio HB
    Br J Dermatol; 2015 Mar; 172(3):754-9. PubMed ID: 25041291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
    JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.